Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan.
about
SLC36A4 (hPAT4) is a high affinity amino acid transporter when expressed in Xenopus laevis oocytesAmino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2)The Concise Guide to PHARMACOLOGY 2013/14: transporters.Transport of the areca nut alkaloid arecaidine by the human proton-coupled amino acid transporter 1 (hPAT1).The proton-coupled amino acid transporter, SLC36A1 (hPAT1), transports Gly-Gly, Gly-Sar and other Gly-Gly mimetics.The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transportHijacking solute carriers for proton-coupled drug transport.Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.PAT1 (SLC36A1) shows nuclear localization and affects growth of smooth muscle cells from rats.Transport of L-proline by the proton-coupled amino acid transporter PAT2 in differentiated 3T3-L1 cells.Delta-aminolevulinic acid is a substrate for the amino acid transporter SLC36A1 (hPAT1).Function and expression of the proton-coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol.Sertraline inhibits the transport of PAT1 substrates in vivo and in vitro.Intestinal absorption of the antiepileptic drug substance vigabatrin is altered by infant formula in vitro and in vivo.Oral and intravenous pharmacokinetics of taurine in sprague-dawley rats: the influence of dose and the possible involvement of the proton-coupled amino acid transporter, PAT1, in oral taurine absorption.Transport of the photodynamic therapy agent 5-aminolevulinic acid by distinct H+-coupled nutrient carriers coexpressed in the small intestine.Rectal absorption of vigabatrin, a substrate of the proton coupled amino acid transporter (PAT1, Slc36a1), in rats.
P2860
Q24307811-9044B039-4652-4A88-9ED2-91AE67DDA250Q28578927-8E9D2D02-7FDD-4952-A918-188D7E811F11Q30486743-C366AC6E-58A6-47EC-BA92-968BE6E36D30Q34332903-24972C29-76C4-4F47-8A8D-3F1611202A01Q34342258-E1B00510-1EA5-46C1-A2EB-89729970D023Q35636089-A8B0D91B-3EE7-47F4-B3F6-F458D9B6AC64Q37824123-28D36855-9075-46D4-BC77-39462472C2A6Q38261962-DFEBA8D6-2607-400D-9BBF-8A49A30BD6DDQ39063741-F63716C6-7C97-451F-89C0-092F1E393900Q39328840-12191A96-85A9-4EFF-AA65-5DC7D8B260BDQ39884569-D4E1BD86-3631-499B-85F2-EB80D85F4909Q41873787-7BA42C93-564C-40B0-ADFC-B2BD3541388CQ41882651-2CE17DFE-D5D7-48C2-B39C-6411D8F50ECDQ42080942-14942D41-6C3E-49BE-8DF3-ED7CB118A784Q42378115-DF7020CA-A762-4616-80D9-112611C7DA1CQ42942526-6BCCD6E2-1672-42DE-B5C9-079DA0100C2DQ48657505-6DC139BD-FFC8-48E0-B555-227B24CC247B
P2860
Intestinal gaboxadol absorption via PAT1 (SLC36A1): modified absorption in vivo following co-administration of L-tryptophan.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Intestinal gaboxadol absorptio ...... dministration of L-tryptophan.
@en
Intestinal gaboxadol absorption via PAT1
@nl
type
label
Intestinal gaboxadol absorptio ...... dministration of L-tryptophan.
@en
Intestinal gaboxadol absorption via PAT1
@nl
prefLabel
Intestinal gaboxadol absorptio ...... dministration of L-tryptophan.
@en
Intestinal gaboxadol absorption via PAT1
@nl
P2093
P2860
P1476
Intestinal gaboxadol absorptio ...... dministration of L-tryptophan.
@en
P2093
P2860
P304
P356
10.1111/J.1476-5381.2009.00253.X
P407
P577
2009-07-07T00:00:00Z